Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
09:00am, Wednesday, 27'th Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Ce
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
07:57pm, Monday, 25'th Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast C
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera F
Natera Issues Statement on Guardant Health Litigation
03:51pm, Monday, 25'th Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
05:31pm, Thursday, 21'st Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed pub
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
08:30am, Thursday, 21'st Nov 2024
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript
11:51pm, Tuesday, 12'th Nov 2024
Natera, Inc. (NASDAQ:NTRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 AM ET Company Participants Mike Brophy - CFO Steve Chapman - CEO Alexey Aleshin - GM Oncology, CMO Conference Call P
Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
07:31pm, Tuesday, 12'th Nov 2024
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
07:00pm, Tuesday, 12'th Nov 2024
Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago.
3 Under-the-Radar Healthcare Companies
08:01am, Monday, 11'th Nov 2024
The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. NYSE: UNH and McKesson Corp. NYSE: MCK to tiny upstart pharmaceuticals firms. Inve
Natera to Participate in Upcoming Investor Conferences
09:00am, Friday, 08'th Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following inv
Natera to Report its Third Quarter 2024 Results on November 12, 2024
09:00am, Friday, 01'st Nov 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 20
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
06:11pm, Thursday, 31'st Oct 2024
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold
Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD
06:00am, Thursday, 31'st Oct 2024
The Cigna Group reported a $739 million third quarter profit despite a $1 billion loss on its investment in clinic operator VillageMD.
All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy
01:01pm, Wednesday, 23'rd Oct 2024
Natera (NTRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
